Bio Pharma Dive

JULY 31, 2024

sales of Shingrix, the shingles vaccine that's become one of the British pharma's top sellers. Several factors are slowing U.S.

Vaccination 278

Vaccination Vaccine Sales 278

Pharmaceutical Technology

SEPTEMBER 3, 2024

The UK NHS has commenced its first-ever vaccination programme for RSV vaccine, targeting pregnant women and older adults.

Vaccination 130

Vaccination Vaccine 130

Pharmaceutical Technology

JUNE 25, 2024

1 Covid-19 vaccine, NVX-CoV2705, for people aged 12 years and above. Novavax has sought EMA approval for its updated JN.1

Vaccination 321

Vaccination Vaccine 321

Pharmaceutical Technology

AUGUST 1, 2024

Valneva and LimmaTech have signed a deal to potentially develop the first marketed shigellosis vaccine.

Vaccination 246

Vaccination Vaccine Development Marketing 246

Pharmaceutical Technology

JUNE 3, 2024

Moderna has secured approval from the US Food and Drug Administration (FDA) for mRESVIA (respiratory syncytial virus vaccine).

FDA Approval 246

FDA Approval Vaccination Vaccine Drugs 246

Pharmaceutical Technology

AUGUST 16, 2024

While the vaccine demonstrated high responses for neutralizing influenza A titers, it failed to show sufficient efficacy against influenza B.

Vaccination 246

Vaccination Vaccine 246

Pharmaceutical Technology

MAY 1, 2024

AstraZeneca has maintained that while the vaccine may, in “very rare” cases, cause TTS, the casual mechanism for this effect remains unknown.

Vaccination 364

Vaccination Vaccine 364

Pharmaceutical Technology

FEBRUARY 12, 2024

vaccine targeting Omicron variant. The UK MHRA has granted approval for a variation in licence of Pfizer-BioNTech’s Comirnaty XBB.1.5

Vaccination 357

Vaccination Vaccine 357

Bio Pharma Dive

MAY 1, 2024

Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ahead.

Sales 286

Sales Vaccination Vaccine Drugs 286

Pharmaceutical Technology

JULY 30, 2024

GSK has announced a strategic collaboration with Flagship Pioneering for the discovery and development of medicines and vaccines.

Medicine 244

Medicine Vaccination Vaccine Development 244

Pharmaceutical Technology

MAY 10, 2024

The FDA approved WestGene’s mRNA therapeutic cancer vaccine as mRNA cancer vaccine development rises in popularity.

FDA Approval 279

FDA Approval Vaccination Vaccine Development 279

Pharmaceutical Technology

SEPTEMBER 11, 2024

Sanofi has announced the inauguration its new modular vaccine and biomedicine production unit, Modulus, in Neuville-sur-Saône, France.

Vaccination 130

Vaccination Vaccine Production 130

Pharmaceutical Technology

JANUARY 29, 2024

The rapid sequencing of the SARS-CoV-2 and the subsequent development of mRNA vaccines led to the authorisation of the first of these vaccines in late 2020.

Vaccination 278

Vaccination Vaccine Development 278

Bio Pharma Dive

MARCH 1, 2024

The expert committee is discussing whether, for certain older adults, to make a universal recommendation for vaccination, rather than the current policy of “shared decisionmaking.”

Vaccination 282

Vaccination Vaccine 282

Bio Pharma Dive

APRIL 1, 2024

The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.

Vaccination 258

Vaccination Vaccine Development 258

Pharmaceutical Technology

MAY 15, 2024

The US agency rejected the expanded use of Dynavax’s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data.

Vaccination 246

Vaccination Vaccine 246

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

RNA 345

RNA Vaccination Vaccine Trials 345

Bio Pharma Dive

OCTOBER 23, 2023

The clearance of the pentavalent shot Penbraya adds to Pfizer’s infectious disease portfolio as it adjusts to slumping COVID-19 vaccine sales.

FDA Approval 306

FDA Approval Vaccination Vaccine Sales 306

Pharmaceutical Technology

AUGUST 23, 2024

The US FDA has approved and granted EUA for Moderna and Pfizer-BioNTech’s updated mRNA Covid-19 vaccines, Comirnaty and Spikevax.

FDA Approval 147

FDA Approval Vaccination Vaccine 147

Pharmaceutical Technology

MAY 9, 2024

Anixa Biosciences has expanded its partnership with Cleveland Clinic to develop additional vaccines for cancers.

Vaccination 246

Vaccination Vaccine Development 246

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%

Vaccination 276

Vaccination Vaccine Development Clinical Trials 276

Pharmaceutical Technology

SEPTEMBER 12, 2024

The vaccine manufacturer said it could also supply 13 million doses by YE 2025 to meet requests by Africa CDC and UNICEF.

Vaccination 130

Vaccination Vaccine Manufacturing 130

Pharmaceutical Technology

FEBRUARY 26, 2024

SK bioscience has achieved a significant milestone with its typhoid conjugate vaccine, SKYTyphoid, receiving WHO prequalification.

Vaccination 244

Vaccination Vaccine 244

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.

Vaccination 298

Vaccination Vaccine Protein Medicine 298

Bio Pharma Dive

JULY 3, 2024

The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.

Vaccination 169

Vaccination Vaccine Licensing Licensing 169

Pharmaceutical Technology

MARCH 14, 2023

The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years.

Vaccination 286

Vaccination Vaccine Clinical Trials Clinical Trials 286

AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 19, 2024

The Indian Council of Medical Research (ICMR) and Panacea Biotec have announced the initiation of the first-ever phase 3 clinical trial for a dengue vaccine in India. The trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.

Clinical Trials 157

Clinical Trials Clinical Trials Vaccination Vaccine 157

Pharmaceutical Technology

FEBRUARY 7, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.

Vaccination 264

Vaccination Vaccine Genetics Trials 264

Pharmaceutical Technology

APRIL 14, 2023

Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.

Vaccination 279

Vaccination Vaccine Manufacturing Containment 279

Pharmaceutical Technology

APRIL 3, 2023

The World Health Organisation (WHO) has revised its recommendations regarding the use of Covid-19 vaccines following a meeting of the agency’s Strategic Advisory Group of Experts on Immunisation (SAGE). The panel emphasised that the extra booster dose recommendation only pertains to one shot and is not for continued annual booster vaccines.

Vaccination 278

Vaccination Vaccine 278

Bio Pharma Dive

JANUARY 23, 2023

Agency scientists are proposing to update COVID shots once a year to match circulating coronavirus strains, as well as simplifying current vaccination regimens.

Vaccination 317

Vaccination Vaccine Scientist 317

Pharmaceutical Technology

JUNE 9, 2023

5+delta) protein vaccine (Sf9 cell). This marks the world’s first Covid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2. The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University. recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta)

Vaccination 269

Vaccination Vaccine HR Protein 269

AuroBlog - Aurous Healthcare Clinical Trials blog

MAY 1, 2024

Scientists have developed a vaccine against a notorious drug-resistant superbug, targeting molecules on its surface that are also found on other bacteria and fungi.

Vaccination 195

Vaccination Vaccine Bacteria Drugs 195

Pharmaceutical Technology

NOVEMBER 29, 2023

Japan’s MHLW has approved CSL and Arcturus Therapeutics’ self-amplifying mRNA (sa-mRNA) Covid-19 vaccine, ARCT-154.

Vaccination 312

Vaccination Vaccine 312

Pharmaceutical Technology

MARCH 25, 2024

Cancer Research UK and the CRIS Cancer Foundation have awarded a £1.7m ($2.1m) grant for developing the lung cancer vaccine LungVax.

Vaccination 246

Vaccination Vaccine Research Development 246

Pharmaceutical Technology

JULY 25, 2024

The UK MHRA has authorised Pfizer-BioNTech’s adapted Comirnaty vaccine against the JN.1 1 Covid-19 subvariant for adults and children.

Vaccination 147

Vaccination Vaccine 147

Pharmaceutical Technology

NOVEMBER 17, 2023

in funding from the Bill & Melinda Gates Foundation for the bulk manufacturing of needle-free vaccines. Micron Biomedical has received $23.6m

Vaccination 264

Vaccination Vaccine Manufacturing 264